APA (7th ed.) Citation

Ardicli, D., Nowak, K., Haliloglu, G., Goullee, H., Davis, M., Talim, B., . . . Topaloğlu, H. (2017). P.331 - Utility of a next-generation sequencing (NGS)-based neuromuscular disease gene panel in an investigation of 30 families with early-onset presentation from a tertiary pediatric neuromuscular clinic. Neuromuscular Disorders, 27, S196. https://doi.org/10.1016/j.nmd.2017.06.371

Chicago Style (17th ed.) Citation

Ardicli, D., K. Nowak, G. Haliloglu, H. Goullee, M. Davis, B. Talim, N. Laing, and H. Topaloğlu. "P.331 - Utility of a Next-generation Sequencing (NGS)-based Neuromuscular Disease Gene Panel in an Investigation of 30 Families with Early-onset Presentation from a Tertiary Pediatric Neuromuscular Clinic." Neuromuscular Disorders 27 (2017): S196. https://doi.org/10.1016/j.nmd.2017.06.371.

MLA (9th ed.) Citation

Ardicli, D., et al. "P.331 - Utility of a Next-generation Sequencing (NGS)-based Neuromuscular Disease Gene Panel in an Investigation of 30 Families with Early-onset Presentation from a Tertiary Pediatric Neuromuscular Clinic." Neuromuscular Disorders, vol. 27, 2017, p. S196, https://doi.org/10.1016/j.nmd.2017.06.371.